Table 1.

ESGO/ESTRO/ESP 2020 recommendations on risk stratification after “ProMisE” genomic classification (right) compared to clinical risk stratification (left).

Risk Group	Molecular Classification Unknown 2020 ESGO/ESTRO/ESP	Molecular Classification Known
Low	Stage IA endometrioid, grade 1–2, LVSI negative or focal	Stage I–II POLE EDM endometrial carcinoma, no residual disease Stage IA MMRd/p53 wt endometrioid carcinoma + low grade + LVSI negative or focal
Intermediate	Stage IB endometrioid, grade 1–2, LVSI negative or focal Stage IA endometrioid, grade 3, LVSI negative or focal Stage IA non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, mixed) without myometrial invasion	Stage IB MMRd/p53 wt endometrioid carcinoma + low-grade + LVSI negative or focal Stage IA MMRd/p53 wt endometrioid carcinoma + high-grade + LVSI negative or focal Stage IA p53abn and/or non-endometrioid without myometrial invasion
High-intermediate	Stage I endometrioid, substantial LSVI, regardless of grade and depth of invasion Stage IB endometrioid, grade 3, regardless of LVSI status Stage II	Stage I MMRd/p53 wt endometrioid carcinoma + substantial LVSI regardless of grade and depth of invasion Stage IB MMRd/p53 wt endometrioid carcinoma high-grade regardless of LVSI status Stage II MMRd/p53 wt endometrioid carcinoma
High	Stage III–IVA with no residual disease Stage I–IVA non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, mixed) with myometrial invasion, and with no residual disease	Stage III–IVA MMRd/p53 wt endometrioid carcinoma with no residual disease Stage I–IVA p53abn endometrial carcinoma with myometrial invasion, with no residual disease Stage I–IVA p53 wt/MMRd serous, undifferentiated carcinoma, carcinosarcoma with myometrial invasion, with no residual disease
Advanced	Stage III–IVA with residual disease	Stage III–IVA with residual disease of any molecular type
Metastatic	Stage IVB	Stage IVB of any molecular type